SavedAdd your journal

Journals / Astım Allerji İmmünoloji / 2021 / Cilt: 19 - Sayı: 1

Management and Successful Desensitization in a Patient with Abatacept-Induced Anaphylaxis

Ferda BİLGİR
Gökhan KABADAYI
Servet AKAR
Pages
46–49
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The rapid desensitization protocol performed with prior premedication wassuccessful and the patient was able to receive subsequent doses of abatacept using the same protocol.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Abatacept is a fusion protein that blocks T cell activation.
📊
Key Findings & Data:It is used in a variety of conditions including organ transplantation, immunedeficiency, and autoimmune diseases.
💡
Conclusion & Impact:The rapid desensitization protocol performed with prior premedication wassuccessful and the patient was able to receive subsequent doses of abatacept using the same protocol.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Abatacept is a fusion protein that blocks T cell activation. It is used in a variety of conditions including organ transplantation, immunedeficiency, and autoimmune diseases. Even though abatacept-induced adverse events are observed, hypersensitivity reactions arerare. Desensitization protocols that can be implemented in the case of hypersensitivity reactions are present in the literature for manybiological agents. However, a desensitization protocol for abatacept has not yet been established.Our patient, who was started on one of the biological agents, abatacept, for rheumatoid arthritis due to insufficient response to diseasemodifying antirheumatic drugs, developed immediate hypersensitivity reaction with the first dose. Since it was planned to continuethe treatment, abatacept desensitization was performed. The rapid desensitization protocol performed with prior premedication wassuccessful and the patient was able to receive subsequent doses of abatacept using the same protocol.

🔖

Cite This Article

BİLGİR, F., KABADAYI, G., AKAR, S. (2021). Management and Successful Desensitization in a Patient with Abatacept-Induced Anaphylaxis. Astım Allerji İmmünoloji, Cilt: 19 - Sayı: 1, 46–49. https://ajindex.com/articles/351216

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Baldo BA.Chimeric fusion proteins used for therapy: Indications, mechanisms, and safety. Drug Saf 2015;38(5):455-79
  2. Choy EH. T-cell costimulation and other directed therapies. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds). Rheumatology. 5th ed. Philadelphia: Mosby, Elsevier; 2015:468-71
  3. Cutolo M, Nadler SG. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev 2013;12:758- 67
  4. Herrero-Beaumont G, Martínez Calatrava MJM, Castaneda S. Abatacept mechanism of action: Concordance with its clinical profile. Reumatol Clin 2012;8:78-83
  5. Abdelshaeed R, Griffiths GB, Neighbour H. Use of abatacept in eosinophilic asthma. J Allergy Clin Immunol Pract 2014;2(2):220-1
  6. Maazi H, Shirinbak S, den Boef LE, Fallarino F, Volpi C, Nawijn MC, et al. Cytotoxic T lymphocyte antigen 4-immunoglobulin G is a potent adjuvant for experimental allergen immunotherapy. Clin Exp Immunol 2013;172(1):113-20
  7. Salmon JH, Perotin JM, Morel J, Dramé M, Cantagrel A, Ziegler LE, et al; French Society of Rheumatology. Serious infusionrelated reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: Prospective registry data. Rheumatology (Oxford) 2018;57(1):134-9
  8. Stinco G, Bergamo S, Frattasio A, di Meo N, Trevisan G. Atopic dermatitis flare during abatacept therapy. J Cutan Med Surg 2014;18(6):369-70
  9. Bao J, Li T, Zhao J, Zhang CY. Cytotoxic T lymphocyte-associated antigen 4 Ig-induced asthma in the treatment of rheumatoid arthritis. J Rheumatol 2012;39(9):1903
  10. Tiwari SM, Wood BA, Skender-Kalnenas T, Cook N. A case of abatacept associated neutrophilic dermatosis and a review of the literature. Australas J Dermatol 2014;55(3):214-7
  11. Conde-Montero E, Baniandrés-Rodríguez O, MendozaCembranos MD, Horcajada-Reales C, Suárez-Fernández R. Psoriasiform reactions during treatment with abatacept.Indian J Dermatol Venereol Leprol 2014;80(1):92-3
  12. Kato K, Satoh T, Nishizawa A, Yokozeki H. Psoriasiform drug eruption due to abatacept. Acta Derm Venereol 2011;91:362-3
  13. Zembiec-Wheeler B, Lott-Limbach A, Malmström H, Elad S. Oral lichenoid reactions may possibly be associated with abatacept: A case report and literature update. Oral Surg Oral Med Oral Pathol Oral Radiol 2018;126(5):e245-51
  14. Yun H, Xie F, Beyl RN, Chen L, Lewis JD, Saag KG, et al. Risk of hypersensitivity to biologic agents among medicare patients with rheumatoid arthritis. A